Front Immunol
. 2023 Sep 11;14:1232472.
doi: 10.3389/fimmu.2023.1232472. eCollection 2023. Rationale for combined therapies in severe-to-critical COVID-19 patients
Aitor Gonzaga 1 2 , Etelvina Andreu 1 3 , Luis M Hernández-Blasco 1 , Rut Meseguer 1 4 , Karima Al-Akioui-Sanz 1 5 , Bárbara Soria-Juan 6 , Jose Carlos Sanjuan-Gimenez 1 , Cristina Ferreras 5 , Juan R Tejedo 7 8 , Guillermo Lopez-Lluch 9 , Rosa Goterris 4 , Loreto Maciá 10 , Jose M Sempere-Ortells 1 11 , Abdelkrim Hmadcha 7 12 , Alberto Borobia 13 , Jose L Vicario 14 , Ana Bonora 15 , Cristobal Aguilar-Gallardo 15 , Jose L Poveda 15 , Cristina Arbona 16 , Cristina Alenda 1 , Fabian Tarín 1 , Francisco M Marco 1 17 , Esperanza Merino 1 18 19 , Francisco Jaime 1 , José Ferreres 20 , Juan Carlos Figueira 21 , Carlos Cañada-Illana 22 , Sergio Querol 23 , Manuel Guerreiro 24 , Cristina Eguizabal 25 26 , Alejandro Martín-Quirós 22 , Ángel Robles-Marhuenda 27 , Antonio Pérez-Martínez 5 28 , Carlos Solano 29 , Bernat Soria 1 2 8
Affiliations
An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19's pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.
Keywords: COVID-19; SARS-CoV-2; advanced therapies; cytokine storm; immunomodulation; mesenchymal stromal cells.
. 2023 Sep 11;14:1232472.
doi: 10.3389/fimmu.2023.1232472. eCollection 2023. Rationale for combined therapies in severe-to-critical COVID-19 patients
Aitor Gonzaga 1 2 , Etelvina Andreu 1 3 , Luis M Hernández-Blasco 1 , Rut Meseguer 1 4 , Karima Al-Akioui-Sanz 1 5 , Bárbara Soria-Juan 6 , Jose Carlos Sanjuan-Gimenez 1 , Cristina Ferreras 5 , Juan R Tejedo 7 8 , Guillermo Lopez-Lluch 9 , Rosa Goterris 4 , Loreto Maciá 10 , Jose M Sempere-Ortells 1 11 , Abdelkrim Hmadcha 7 12 , Alberto Borobia 13 , Jose L Vicario 14 , Ana Bonora 15 , Cristobal Aguilar-Gallardo 15 , Jose L Poveda 15 , Cristina Arbona 16 , Cristina Alenda 1 , Fabian Tarín 1 , Francisco M Marco 1 17 , Esperanza Merino 1 18 19 , Francisco Jaime 1 , José Ferreres 20 , Juan Carlos Figueira 21 , Carlos Cañada-Illana 22 , Sergio Querol 23 , Manuel Guerreiro 24 , Cristina Eguizabal 25 26 , Alejandro Martín-Quirós 22 , Ángel Robles-Marhuenda 27 , Antonio Pérez-Martínez 5 28 , Carlos Solano 29 , Bernat Soria 1 2 8
Affiliations
- PMID: 37767093
- PMCID: PMC10520558
- DOI: 10.3389/fimmu.2023.1232472
An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19's pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.
Keywords: COVID-19; SARS-CoV-2; advanced therapies; cytokine storm; immunomodulation; mesenchymal stromal cells.